A review of one research paper.

Our review questions

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU

Study review

In preparation

Not independently approved.

Paper published: Not recorded

Study at a glance

DOI
10.1111/j.1464-5491.2009.02666.x

Key limitation: A full assessment of this paper is not yet available. Its presence in the library does not establish benefit or safety.

0

Review in preparation

This paper has a dedicated review record, but its full study appraisal is not yet available. It has not been counted as a completed review.

0 of 15 questions answered; 0 partly resolved; 15 awaiting assessment.

The original paper and references remain available above.